DL
David Lamond

David Lamond insider trades: Quince Therapeutics (QNCX) stock purchases

Quince Therapeutics Last trade Dec 14, 2023 29 Form 4 filings
$0
Sold, last 12 months
0 sales
$0
Bought, last 12 months
0 buys
12
Open-market trades
since 2020
4
Companies
last trade 2023

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where David reports to the SEC

Open-market buys and sales

12 trades reported on SEC Form 4, newest first

DateStockTypeValue
Dec 14, 2023QNCX↑ Buy$46K
Dec 12, 2023QNCX↑ Buy$23K
Dec 7, 2023QNCX↑ Buy$58K
Dec 1, 2023QNCX↑ Buy$41K
Aug 31, 2023QNCX↑ Buy$108K
Aug 17, 2023QNCX↑ Buy$326K
May 23, 2022AMTI↑ Buy$211K
Apr 6, 2021AMTI↑ Buy$1.1M
Mar 24, 2021CRTX↑ Buy$1.7M
Mar 4, 2021CRTX↑ Buy$1.8M
Jun 4, 2020CRTX↑ Buy$2.1M
May 19, 2020CRTX↑ Buy$2.5M

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

About David Lamond's insider trades

David Lamond is an insider at Quince Therapeutics (QNCX). Since May 19, 2020, David has reported 12 open-market purchases worth $9.9M and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.

Their filings also include grants and awards (15 filings), conversions (3 filings), gifts (1 filing). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every QNCX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.